RECOVER: ME/CFS criteria after SARS-CoV-2 infection
Vernon SD et al. · 2025 · Journal of General Internal Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
The RECOVER analysis applied ME/CFS symptom criteria to survey data in infected and uninfected groups.
Dose, route and schedule
The RECOVER analysis applied ME/CFS symptom criteria to survey data in infected and uninfected groups.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Meeting ME/CFS criteria | 531/11,785 (4.5%) after SARS-CoV-2 infection versus 9/1,439 (0.6%) in the uninfected comparison. |
These are proportions within the recruited cohort. Referral and participation can affect absolute rates.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- These are proportions within the recruited cohort. Referral and participation can affect absolute rates.
Related publications may cover the same research program or participants.
Source access
The RECOVER analysis applied ME/CFS symptom criteria to survey data in infected and uninfected groups.
Source reviewed 2026-11-12.
Citation and original source
Original source: Vernon SD et al.. RECOVER: ME/CFS criteria after SARS-CoV-2 infection Journal of General Internal Medicine 2025.
Molekul research summary: https://molekul.io/research/recover-post-covid-mecfs-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry